Pyrrolidino-4-iodotamoxifen and 4-Iodotamoxifen, New Analogues of the Antiestrogen Tamoxifen for the Treatment of Breast Cancer

Cancer Research

Volumn 51, Issue 21, 1991, Pages 5851-5858

  Chander, S K ^a,e   Jarman, M ^c,d   Coombes, R C ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b Dept of Academic Biochemistry ^*  (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d CRC Drug Development Dept ^*  (United Kingdom)

^e IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 IODOTAMOXIFEN; ESTROGEN RECEPTOR; IDOXIFENE; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; INTRAMUSCULAR DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING;

ANIMAL; BREAST NEOPLASMS; CELL DIVISION; CELL LINE; COMPARATIVE STUDY; DRUG SCREENING ASSAYS, ANTITUMOR; ESTROGENS, SYNTHETIC; FEMALE; HUMAN; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; RATS; RATS, INBRED STRAINS; RECEPTORS, ESTROGEN; SUPPORT, NON-U.S. GOV'T; TAMOXIFEN;

EID: 0026345105     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Furr, B. J., and Jordan, V. C. The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther., 25: 127-205,1984.
2. Nolvadex Adjuvant Trial Organization. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Lancet, /; 836-839, 1985.
3. Nolvadex Adjuvant Trial Organization. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br. J. Cancer, 57:608-611, 1988.
4. Scottish Breast Cancer Trials Committee. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancet, 2: 171-175, 1987.
5. Mouridsen, H., Palshof, T., Patterson, J., and Battersby, L. Tamoxifen in advanced breast cancer. Cancer Treat. Rep., 5: 131-141, 1978.
6. Tormey, D. C., Simon, R. M., Lippman, M. E., Bull, J. M., and Meyer, C. E. Evaluation of tamoxifen dose in advanced breast cancer: a progress report. Cancer Treat. Rep., 60: 1451-1459,1976.
7. McIntosh, I. H., and Thynne, G. S. Tumor stimulation by antiestrogens. Br. J. Surg., 64:900-901,1979.
8. Plotkin, D., Lecher, J., Jung, W. E., and Risen, P. J. Tamoxifen flare in advanced breast cancer. JAMA, 240: 2644-2646,1978.
9. Smith, I. E., Harris, A. L., Morgan, M., Ford, H. T., Gazet, J. C., Harmes, C. L., White, H., Parsons, C. A., Villardo, A., Walsh, G., and McKinna, J. A. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. BMJ, 283:1432-1434,1981.
10. Murray, R. M. L., and Pitt, P. Aminoglutethimide in tamoxifen-resistant patients: the Melbourne experience. Cancer Res., 42 (Suppl.); 3437s-3441s, 1982.
11. Buzdar, A. O., Powell, K. C., and Blumenschein, G. R. Aminoglutethimide after tamoxifen therapy in advanced breast cancer: M. D. Anderson Hospital experience. Cancer Res., 42 (Suppl.); 3448s-3450s, 1982.
12. Jordan, V. C., and Gosden, B. Inhibition of the uterotrophic activity of 13. Clemens, J. A., Bennett, D. R., Black, L. J., and Jones, C. D. Effect of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci., 32:2869-2875,1983.
13. Gottardis, M. M., and Jordon, V. C. The antitumor actions of keoxifene and tamoxifen in the /V-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res., 47:4020-4024, 1987.
14. Lemer, L. J. The first non-steroidal antiestrogen-MER 25. In: R. C. Sutherland and V. C. Jordan (eds.), Non-steroidal Antiestrogen, pp. 1-16. Sydney: Academic Press, 1981.
15. Nicholson, R. L. Antiestrogens and breast cancer therapy. In: B. J. A. Furr and A. E. Wakeling (eds.), Pharmacology and Clinical Uses of Inhibitor of Hormone Secretion and Action, pp. 60-86. London: Bailliere-Tindall, 1986.
16. McCague, R., Leclerq, G., Legros, N., Goodman, J., Blackburn, G. M., Jarman, M., and Foster, A. B. Derivatives of tamoxifen. Dependence of antiestrogenity on the 4-substituent. J. Med. Chem., 32:2527-2533, 1989.
17. McCague, R. Halogenated tamoxifens. British Patent Application No. 8621908/ 1986.
18. Wakeling, A. E. Anti-hormones and other steroid analogues. In: B. Green and R. E. Leake (eds.), Steroid Hormones: A Practical Approach, pp. 219-236. Oxford: IRL Press, 1987.
19. Wilkinson, J. R., Williams, J. C., Singh, D., Goss, P. E., Easton, D., and Coombes, R. C. Response of nitrosomethylurea-induced rat mammary tumor to endocrine therapy and comparison with clinical response. Cancer Res., 46:4862-4865, 1986.
20. Wakeling, A. E., Valcaccia, B., Newboult, E. E., and Green, L. R. Steroidal antiestrogens-receptor binding and biological response in rat uterus, rat mammary carcinoma, and human breast cancer cells. J. Steroid Biochem., 20:111-120,1984.
21. Black, L. J., and Goode, L. Uterine bioassay of tamoxifen, trioxifene, and a new estrogen antagonist (LY117018) in rats and mice. Life Sci., 26: 1453-1458, 1980.
22. Harper, M. J. K., and Walpole, A. L. A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J. Reprod. Fertil., 13: 101-119, 1967.
23. Jordan, V. C., and Allen, K. E. Evaluations of the antitumor activity of the nonsteroidal antiestrogen, monohydroxytamoxifen, in the DMBA induced rat mammary carcinoma model. Eur. J. Cancer, 16:239;-251, 1980.
24. McCague, R., Parr, I. B., Leclerq, G., Leung, O-T., and Jarman, M. Metabolism of tamoxifen by isolated rat hepatocytes. Identification of the glucu-ronide of 4-hydroxytamoxifen. Biochem. Pharmacol., 39:1459-1465,1990.
25. Robertson, D. W., Katzenellenbogen, J. A., Hayes, J. R., and Katzenellenbogen, B. S. Antiestrogen basicity-activity relationships: a comparison of the estrogen receptor binding and antiuterotrophic potencies of several analogues of (Z)-1,2-diphenyl-1 -{4-[2-(dimethylamino)ethoxy]phenyl}-1 -butene (tamoxifen, nolvadex) having altered basicity. J. Med. Chem., 25:167-171, 1982.
26. Allen, K. E., Clark, E. R., and Jordan, V. C. Evidence for the metabolic activation of non-steroidal antiestrogens: a study of structure-activity relationship. Br. J. Pharmacol., 71:83-91, 1980.
27. Wakeling, A. E., and Bowler, J. Novel antiestrogens without partial agonist activity. J. Steroid Biochem., 31:645-653, 1988.
28. McNab, M. W., Tallarida, R. J., and Joseph, R. An evaluation of tamoxifen as a partial agonist by classical receptor theory-an explanation of the dual action of tamoxifen. Eur. J. Pharmacol., 103:321-326, 1984.
29. Wakeling, A. E. Pharmacology of antiestrogens. In: B. J. A. Furr and A. E. Wakeling (eds.), Pharmacology and Clinical Uses of Inhibitors of Hormones Secretion and Action, pp. 1-9. London: Bailliere-Tindall, 1986.
30. Black, L. J., Jones, C. D., and Falcone, J. F. Antagonism of estrogen action with new benzothiophene-derived antiestrogen. Life Sci., 32: 1031-1036, 1983.
31. Wakeling, A. E., and Bowler, J. Biology and mode of action of pure antiestrogens. J. Steroid Biochem., 30: 141-147,1988.
32. Wilson, A. P. M., Weatherill, P. J., Nicholson, R. I., Davies, P., and Wakeling, A. E. A comparative study of the interaction of estradiol and the steroidal pure antiestrogen, ICI 164,384, with the molybdate-stabilized estrogen receptor. J. Steroid Biochem., 35:421-428, 1990.
33. Green, S. Modulation of estradiol receptor activity by estrogens and antiestrogens. J. Steroid Biochem. Molec. Biol., 37:747-751, 1990.